Top-Rated StocksTop-RatedNASDAQ:SNDX Syndax Pharmaceuticals (SNDX) Stock Price, News & Analysis $19.10 -0.50 (-2.55%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$19.06▼$19.6950-Day Range$19.10▼$24.8152-Week Range$11.22▼$25.34Volume401,403 shsAverage Volume686,205 shsMarket Capitalization$1.63 billionP/E RatioN/ADividend YieldN/APrice Target$35.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Syndax Pharmaceuticals alerts: Email Address Syndax Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside85.0% Upside$35.33 Price TargetShort InterestBearish11.08% of Shares Sold ShortDividend StrengthN/ASustainability-1.12Upright™ Environmental ScoreNews Sentiment0.90Based on 4 Articles This WeekInsider TradingAcquiring Shares$25,038 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($3.66) to ($3.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.29 out of 5 starsMedical Sector120th out of 910 stocksPharmaceutical Preparations Industry44th out of 426 stocks 4.5 Analyst's Opinion Consensus RatingSyndax Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSyndax Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Syndax Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.08% of the outstanding shares of Syndax Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverSyndax Pharmaceuticals has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Syndax Pharmaceuticals has recently increased by 9.78%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSyndax Pharmaceuticals does not currently pay a dividend.Dividend GrowthSyndax Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSyndax Pharmaceuticals has received a 66.26% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Syndax Pharmaceuticals is -1.12. Previous Next 2.7 News and Social Media Coverage News SentimentSyndax Pharmaceuticals has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Syndax Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest8 people have searched for SNDX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Syndax Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Syndax Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $25,038.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.10% of the stock of Syndax Pharmaceuticals is held by insiders.Read more about Syndax Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Syndax Pharmaceuticals are expected to grow in the coming year, from ($3.66) to ($3.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Syndax Pharmaceuticals is -5.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syndax Pharmaceuticals is -5.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyndax Pharmaceuticals has a P/B Ratio of 3.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Syndax Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWhy billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. Click here for my exclusive video About Syndax Pharmaceuticals Stock (NASDAQ:SNDX)Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Read More SNDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNDX Stock News HeadlinesSeptember 6 at 4:05 PM | prnewswire.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)September 5 at 9:30 AM | msn.comSyndax Pharmaceuticals, Inc. (SNDX): This Small-Cap Healthcare Stock Is A Good Buy Right NowSeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 28, 2024 | americanbankingnews.comBrokerages Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Target Price at $35.33August 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Syndax Pharmaceuticals Amid Niktimvo’s Promising Market Entry and EfficacyAugust 15, 2024 | finance.yahoo.comFDA greenlights Incyte and Syndax’s GvHD drug NiktimvoAugust 15, 2024 | finance.yahoo.comFDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant ComplicationAugust 12, 2024 | prnewswire.comSyndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute LeukemiaSeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 5, 2024 | prnewswire.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)August 3, 2024 | msn.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q2 2024 Earnings Call TranscriptAugust 3, 2024 | finance.yahoo.comDespite currently being unprofitable, Syndax Pharmaceuticals (NASDAQ:SNDX) has delivered a 113% return to shareholders over 5 yearsAugust 2, 2024 | markets.businessinsider.comBuy Rating Affirmed on Syndax Pharmaceuticals Amid Strong Trial Results and Solid Financial PositionAugust 2, 2024 | markets.businessinsider.comStrong Buy Rating for Syndax Pharmaceuticals Amid Positive Drug Approval ProspectsAugust 1, 2024 | msn.comSyndax's revumenib granted FDA orphan drug designation for leukemiaAugust 1, 2024 | prnewswire.comSyndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business UpdateJuly 31, 2024 | markets.businessinsider.comMaintained Buy Rating on Syndax Pharmaceuticals Amid Revumenib Approval DelayJuly 30, 2024 | investorplace.com3 Biotech Stocks That Could Make Your Summer UnforgettableSee More Headlines Receive SNDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SNDX CUSIPN/A CIK1395937 Webwww.syndax.com Phone(781) 419-1400Fax781-419-1420Employees110Year FoundedN/APrice Target and Rating Average Stock Price Target$35.33 High Stock Price Target$45.00 Low Stock Price Target$23.00 Potential Upside/Downside+85.0%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($3.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-209,360,000.00 Net MarginsN/A Pretax Margin-7,545.20% Return on Equity-57.42% Return on Assets-51.98% Debt Debt-to-Equity RatioN/A Current Ratio10.50 Quick Ratio10.50 Sales & Book Value Annual Sales$139.71 million Price / Sales11.63 Cash FlowN/A Price / Cash FlowN/A Book Value$5.10 per share Price / Book3.75Miscellaneous Outstanding Shares85,100,000Free Float81,503,000Market Cap$1.63 billion OptionableOptionable Beta0.91 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Michael A. Metzger M.B.A. (Age 53)CEO & Director Comp: $1.1MDr. Peter Ordentlich B.Sc. (Age 55)Ph.D., Co-Founder & Chief Scientific Officer Dr. Richard A. Heyman Ph.D. (Age 67)Co-Founder Dr. Ronald M. Evans Ph.D. (Age 75)Co-Founder, Advisor and Chair of Scientific Advisory Board Dr. Michael Downes Ph.D.Co-FounderSharon KlahreVice President of Investor Relations & CommunicationsMr. Kevin McManus (Age 55)Chief People Officer Dr. Joseph Paul Eder M.D.Member of Scientific Advisory Board & Chief Medical OfficerDr. Anjali Ganguli Ph.D. (Age 47)Chief Business Officer Comp: $450.58kMr. Steven ClosterChief Commercial OfficerMore ExecutivesKey CompetitorsAmphastar PharmaceuticalsNASDAQ:AMPHEnanta PharmaceuticalsNASDAQ:ENTAViking TherapeuticsNASDAQ:VKTXCytokineticsNASDAQ:CYTKBlueprint MedicinesNASDAQ:BPMCView All CompetitorsInsiders & InstitutionsNantahala Capital Management LLCSold 12,027 shares on 8/20/2024Ownership: 0.533%Algert Global LLCBought 6,455 shares on 8/16/2024Ownership: 0.508%Creative PlanningBought 3,962 shares on 8/16/2024Ownership: 0.022%Quarry LPBought 2,625 shares on 8/16/2024Ownership: 0.007%Northwestern Mutual Wealth Management Co.Bought 1,300 shares on 8/16/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions SNDX Stock Analysis - Frequently Asked Questions How have SNDX shares performed this year? Syndax Pharmaceuticals' stock was trading at $21.61 at the beginning of the year. Since then, SNDX stock has decreased by 11.6% and is now trading at $19.10. View the best growth stocks for 2024 here. How were Syndax Pharmaceuticals' earnings last quarter? Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) posted its quarterly earnings data on Thursday, August, 1st. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.11. The business's revenue for the quarter was up 3499999990.0% compared to the same quarter last year. When did Syndax Pharmaceuticals IPO? Syndax Pharmaceuticals (SNDX) raised $66 million in an IPO on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers. Who are Syndax Pharmaceuticals' major shareholders? Syndax Pharmaceuticals' top institutional shareholders include Avoro Capital Advisors LLC (4.57%), Sofinnova Investments Inc. (2.53%), Marshall Wace LLP (2.15%) and Millennium Management LLC (1.25%). Insiders that own company stock include Dennis Podlesak, William Meury, Keith Katkin, Pierre Legault, Briggs Morrison, Michael A Metzger, Alexander Nolte, Peter Ordentlich and Fabrice Egros. View institutional ownership trends. How do I buy shares of Syndax Pharmaceuticals? Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Syndax Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV). This page (NASDAQ:SNDX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syndax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
